GT Biopharma
GTBP
17 hedge funds and large institutions have $349K invested in GT Biopharma in 2024 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 9 reducing their positions, and 18 closing their positions.
5.19% more ownership
Funds ownership: 0.28% → 5.47% (+5.2%)
48% less funds holding
Funds holding: 33 → 17 (-16)
61% less capital invested
Capital invested by funds: $895K → $349K (-$547K)
78% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 9
89% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
+$8.67K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$2.83K |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$322 |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
+$32 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$83.2K |
| 2 |
Renaissance Technologies
New York
|
-$29K |
| 3 |
AWS
Atria Wealth Solutions
New York
|
-$25.2K |
| 4 |
Bank of New York Mellon
New York
|
-$24.3K |
| 5 |
State Street
Boston,
Massachusetts
|
-$20.4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Northern Trust
Chicago,
Illinois
| – | -$8.25K | -1,078 | Closed |
|
|
MG
27
Marex Group
London,
| – | -$7.65K | -1,000 | Closed |
|
28
Goldman Sachs
New York
| – | -$5.83K | -762 | Closed |
|
|
MAWA
29
Moss Adams Wealth Advisors
Seattle,
Washington
| – | -$5.1K | -667 | Closed |
|
30
Jane Street
New York
| – | -$4.95K | -647 | Closed |
|
31
Commonwealth Equity Services
Waltham,
Massachusetts
| – | -$3K | -337 | Closed |
|
|
WG
32
Welch Group
Birmingham,
Alabama
| – | -$2.55K | -333 | Closed |
|
33
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$349 | -66 | -90% |
|
|
ASN
34
Advisory Services Network
Atlanta,
Georgia
| – | -$38 | -5 | Closed |
|
35
Qube Research & Technologies (QRT)
London,
United Kingdom
| – | -$1 | – | – |
|
GTBP Hedge Fund Activity: Q1 2024 in Review
17 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in GT Biopharma (GTBP) for Q1 2024, worth a combined $349K — down 61% from $895K a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of GTBP and 2 opened new positions — a net loss of 16 holders — while 9 trimmed existing stakes and 2 added.
The largest buyer was Tower Research Capital (TRC), adding an estimated $8.67K. The largest seller was Vanguard Group, cutting an estimated $83.2K.
- 17 institutional investors held GT Biopharma (GTBP) as of Q1 2024, down from 33 in Q4 2023.
- Funds reported $349K of GT Biopharma stock for Q1 2024, down 61% quarter-over-quarter.
- 2 funds opened new GT Biopharma positions in Q1 2024 and 18 closed out, a net change of -16 holders.
- The largest GT Biopharma buyer in Q1 2024 was Tower Research Capital (TRC), an estimated $8.67K added.
- The largest GT Biopharma seller in Q1 2024 was Vanguard Group, an estimated $83.2K sold.
Based on aggregated 13F filings for Q1 2024.